NEW YORK, Oct 26 - Rosetta Inpharmatics reported greater-than-expected third quarter 2000 losses Thursday, falling 12 cents per share short of Wall Street’s predictions.

For the third quarter of 2000, the company reported a net loss of $8.4 million, or 40 cents per diluted share, compared to a net loss of $5.0 million, or $1.11 per share for the year-ago period.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.